This 'licenses' DCs to present tumor antigens to naïve CD4+ T cells, or cross‐present to naïve CD8+ T cells, triggering cytokine and chemokine release plus activation and infiltration of tumor‐specific T cells to the tumor bed to target cancer cells.6 This evidence concerns the gene CD4 and neoplasm.